2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices
Cardiometabolic Health Congress
JULY 17, 2024
Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery. The label includes a “black box” warning for CV risk due to blood clots.
59 
Let's personalize your content